{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T23:08:30Z","timestamp":1789427310450,"version":"build-2803163510"},"reference-count":30,"publisher":"Harborside Press, LLC","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> The single-arm phase II DESTINY-Gastric02 (DG-02) study investigated trastuzumab deruxtecan (T-DXd) as second-line therapy in Western patients with HER2-positive unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma that progressed during or after trastuzumab-based first-line therapy. The aim of the current study was to compare patients in the DG-02 study with a real-world reference group of patients who received ramucirumab and paclitaxel (Ram + Pac) as second-line therapy. <jats:bold>Methods:<\/jats:bold> A total of 71 of 79 patients from DG-02 who had received trastuzumab in the metastatic setting were included. A comparable cohort of patients with HER2-positive esophageal, gastric, or GEJ adenocarcinoma who received trastuzumab in the first-line setting and Ram + Pac in the second-line setting was identified from the Netherlands Cancer Registry (NCR; n=120). Propensity score trimming and propensity score were used to select a reference group for DG-02 from patients in the NCR, based on sex, age, ECOG performance status, primary tumor location, body mass index, renal function, number of metastatic sites, presence of liver metastases, and duration of first-line therapy. <jats:bold>Results:<\/jats:bold> Propensity score trimming led to the exclusion of 12 patients from the DG-02 group and 33 patients from the NCR group. Thereafter, propensity score matching resulted in a balanced group of patients from the NCR (n=78) and the DG-02 trial (n=58). Median overall survival was significantly longer among patients treated with T-DXd (11.6 months; 95% CI, 9.0\u201320.5) compared with those treated with the Ram + Pac reference regimen (6.2 months; 95% CI, 4.5\u201310.0; <jats:italic>P<\/jats:italic>&lt;.0001). <jats:bold>Conclusions:<\/jats:bold> Compared with patients with metastatic, trastuzumab-pretreated HER2-positive gastric or GEJ adenocarcinoma who received Ram + Pac, those who received T-DXd as second-line therapy had improved overall survival.<\/jats:p>","DOI":"10.6004\/jnccn.2025.7058","type":"journal-article","created":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T15:01:39Z","timestamp":1757602899000},"source":"Crossref","is-referenced-by-count":2,"title":["Trastuzumab Deruxtecan Versus Ramucirumab-Paclitaxel as Second-Line Therapy for Patients With HER2-Positive Gastric or GEJ Adenocarcinoma"],"prefix":"10.6004","volume":"23","author":[{"given":"Rob H.A.","family":"Verhoeven","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, University of Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands"},{"name":"Cancer Treatment and Quality of Life, Cancer Center Amsterdam, Amsterdam, the Netherlands"},{"name":"Department of Research & Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven C.","family":"Kuijper","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University of Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands"},{"name":"Cancer Treatment and Quality of Life, Cancer Center Amsterdam, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Lordick","sequence":"additional","affiliation":[{"name":"Divisions of Oncology, Gastroenterology, Hepatology, and Pulmonology, Department of Medicine, University of Leipzig Medical Center, Comprehensive Cancer Center Central Germany, Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marije","family":"Slingerland","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Qin","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo Inc., Basking Ridge, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanneke W.M.","family":"van Laarhoven","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University of Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands"},{"name":"Cancer Treatment and Quality of Life, Cancer Center Amsterdam, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"B1","series-title":"Lancet","first-page":"687","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang YJ","year":"2010","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A,  Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687\u2013697."},{"key":"B2","series-title":"Ann Oncol","first-page":"1005","article-title":"Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Lordick F","year":"2022","unstructured":"Lordick F, Carneiro F, Cascinu S,  Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 2022;33:1005\u20131020."},{"key":"B3","series-title":"Int J Cancer","first-page":"438","article-title":"Comparing cytotoxic backbones for first-line trastuzumab-containing regimens in human epidermal growth factor receptor 2-positive advanced oesophagogastric cancer: a meta-analysis","volume":"143","author":"Ter Veer E","year":"2018","unstructured":"Ter Veer E, Creemers A, de Waal L,  Comparing cytotoxic backbones for first-line trastuzumab-containing regimens in human epidermal growth factor receptor 2-positive advanced oesophagogastric cancer: a meta-analysis. Int J Cancer 2018;143:438\u2013448."},{"key":"B4","series-title":"Future Oncol","first-page":"2723","article-title":"Ramucirumab and paclitaxel in patients with gastric cancer and prior trastuzumab: subgroup analysis from RAINBOW study","volume":"15","author":"De Vita F","year":"2019","unstructured":"De Vita F, Borg C, Farina G,  Ramucirumab and paclitaxel in patients with gastric cancer and prior trastuzumab: subgroup analysis from RAINBOW study. Future Oncol 2019;15:2723\u20132731."},{"key":"B5","series-title":"Acta Oncol","first-page":"1599","article-title":"Continuation of trastuzumab beyond progression in HER2-positive advanced esophagogastric cancer: a meta-analysis","volume":"57","author":"Ter Veer E","year":"2018","unstructured":"Ter Veer E, van den Ende T, Creemers A,  Continuation of trastuzumab beyond progression in HER2-positive advanced esophagogastric cancer: a meta-analysis. Acta Oncol 2018;57:1599\u20131604."},{"key":"B6","series-title":"Lancet Oncol","first-page":"1224","article-title":"Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial","volume":"15","author":"Wilke H","year":"2014","unstructured":"Wilke H, Muro K, Van Cutsem E,  Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 2014;15:1224\u20131235."},{"key":"B7","series-title":"N Engl J Med","first-page":"2419","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer","volume":"382","author":"Shitara K","year":"2020","unstructured":"Shitara K, Bang YJ, Iwasa S,  Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med 2020;382:2419\u20132430."},{"key":"B8","series-title":"Lancet Oncol","first-page":"744","article-title":"Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study","volume":"24","author":"Van Cutsem E","year":"2023","unstructured":"Van Cutsem E, di Bartolomeo M, Smyth E,  Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study. Lancet Oncol 2023;24:744\u2013756."},{"key":"B9","series-title":"J Clin Oncol","first-page":"1919","article-title":"Randomized, phase II study of trastuzumab beyond progression in patients with HER2-positive advanced gastric or gastroesophageal junction cancer: WJOG7112G (T-ACT study)","volume":"38","author":"Makiyama A","year":"2020","unstructured":"Makiyama A, Sukawa Y, Kashiwada T,  Randomized, phase II study of trastuzumab beyond progression in patients with HER2-positive advanced gastric or gastroesophageal junction cancer: WJOG7112G (T-ACT study). J Clin Oncol 2020;38:1919\u20131927."},{"key":"B10","series-title":"Ther Adv Med Oncol","first-page":"17588359231162576.","article-title":"Comparing treatment and outcomes in advanced esophageal, gastroesophageal junction, and gastric adenocarcinomas: a population-based study","volume":"15","author":"Pape M","year":"2023","unstructured":"Pape M, Vissers PAJ, Dijksterhuis WPM,  Comparing treatment and outcomes in advanced esophageal, gastroesophageal junction, and gastric adenocarcinomas: a population-based study. Ther Adv Med Oncol 2023;15:17588359231162576."},{"key":"B11","series-title":"Ann Oncol","first-page":"885","article-title":"The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma\u2014individual patient data from 1775 patients in four randomised controlled trials","volume":"20","author":"Chau I","year":"2009","unstructured":"Chau I, Norman AR, Cunningham D,  The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma\u2014individual patient data from 1775 patients in four randomised controlled trials. Ann Oncol 2009;20:885\u2013891."},{"key":"B12","series-title":"Adv Ther","first-page":"707","article-title":"A comparison of real-world treatment patterns and clinical outcomes in patients receiving first-line therapy for unresectable advanced gastric or gastroesophageal junction cancer versus esophageal adenocarcinomas","volume":"38","author":"Shankaran V","year":"2021","unstructured":"Shankaran V, Xiao H, Bertwistle D,  A comparison of real-world treatment patterns and clinical outcomes in patients receiving first-line therapy for unresectable advanced gastric or gastroesophageal junction cancer versus esophageal adenocarcinomas. Adv Ther 2021;38:707\u2013720."},{"key":"B13","series-title":"Ther Adv Med Oncol","first-page":"17588359221109196.","article-title":"A phase Ib\/II study of regorafenib and paclitaxel in patients with beyond first-line advanced esophagogastric carcinoma (REPEAT)","volume":"14","author":"Stroes CI","year":"2022","unstructured":"Stroes CI, Schokker S, Khurshed M,  A phase Ib\/II study of regorafenib and paclitaxel in patients with beyond first-line advanced esophagogastric carcinoma (REPEAT). Ther Adv Med Oncol 2022;14:17588359221109196."},{"key":"B14","series-title":"J Clin Oncol","first-page":"462","article-title":"Phase II feasibility and biomarker study of neoadjuvant trastuzumab and pertuzumab with chemoradiotherapy for resectable human epidermal growth factor receptor 2-positive esophageal adenocarcinoma: TRAP study","volume":"38","author":"Stroes CI","year":"2020","unstructured":"Stroes CI, Schokker S, Creemers A,  Phase II feasibility and biomarker study of neoadjuvant trastuzumab and pertuzumab with chemoradiotherapy for resectable human epidermal growth factor receptor 2-positive esophageal adenocarcinoma: TRAP study. J Clin Oncol 2020;38:462\u2013471."},{"key":"B15","series-title":"Cancers (Basel)","first-page":"1","article-title":"A phase II study demonstrates no feasibility of adjuvant treatment with six cycles of S-1 and oxaliplatin in resectable esophageal adenocarcinoma, with ERCC1 as biomarker for response to SOX","volume":"13","author":"Stroes CI","year":"2021","unstructured":"Stroes CI, Schokker S, Molenaar RJ,  A phase II study demonstrates no feasibility of adjuvant treatment with six cycles of S-1 and oxaliplatin in resectable esophageal adenocarcinoma, with ERCC1 as biomarker for response to SOX. Cancers (Basel) 2021;13:1\u201315."},{"key":"B16","series-title":"Clin Cancer Res","first-page":"3351","article-title":"Neoadjuvant chemoradiotherapy combined with atezolizumab for resectable esophageal adenocarcinoma: a single-arm phase II feasibility trial (PERFECT)","volume":"27","author":"van den Ende T","year":"2021","unstructured":"van den Ende T, de Clercq NC, van Berge Henegouwen MI,  Neoadjuvant chemoradiotherapy combined with atezolizumab for resectable esophageal adenocarcinoma: a single-arm phase II feasibility trial (PERFECT). Clin Cancer Res 2021;27:3351\u20133359."},{"key":"B17","series-title":"Nephron","first-page":"31","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft DW","year":"1976","unstructured":"Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31\u201341."},{"key":"B18","series-title":"Multivariate Behav Res","first-page":"399","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin PC","year":"2011","unstructured":"Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 2011;46:399\u2013424."},{"key":"B19","unstructured":"Mayer M. missRanger: fast imputation of missing values (R package version 2.1). Accessed April 1, 2024. Available at: https:\/\/CRAN.R-project.org\/package=missRanger"},{"key":"B20","series-title":"Stat Med","first-page":"3949","article-title":"Optimal full matching for survival outcomes: a method that merits more widespread use","volume":"34","author":"Austin PC","year":"2015","unstructured":"Austin PC, Stuart EA. Optimal full matching for survival outcomes: a method that merits more widespread use. Stat Med 2015;34:3949\u20133967."},{"key":"B21","series-title":"Rev Econ Stat","first-page":"932","article-title":"Genetic matching for estimating causal effects: a general multivariate matching method for achieving balance in observational studies","volume":"95","author":"Diamond A","year":"2013","unstructured":"Diamond A, Sekhon JS. Genetic matching for estimating causal effects: a general multivariate matching method for achieving balance in observational studies. Rev Econ Stat 2013;95:932\u2013945."},{"key":"B22","article-title":"MatchIt: nonparametric preprocessing for parametric causal inference (R package version 4.5-2)","author":"Ho DE","unstructured":"Ho DE, Imai K, King G, Stuart EA. MatchIt: nonparametric preprocessing for parametric causal inference (R package version 4.5-2). Accessed April 1, 2024. Available at: https:\/\/CRAN.R-project.org\/package=MatchIt"},{"key":"B23","article-title":"A package for survival analysis in R (R package version 3.5-7)","author":"Therneau TM","unstructured":"Therneau TM. A package for survival analysis in R (R package version 3.5-7). Accessed April 1, 2024. Available at: https:\/\/CRAN.R-project.org\/package=survival"},{"key":"B24","series-title":"J Clin Epidemiol","first-page":"344","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"61","author":"von Elm E","year":"2008","unstructured":"von Elm E, Altman DG, Egger M,  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 2008;61:344\u2013349."},{"key":"B25","series-title":"J Cancer Res Clin Oncol","first-page":"4077","article-title":"Does HER2 status influence in the benefit of ramucirumab and paclitaxel as second line treatment of advanced gastro-esophageal adenocarcinoma? Data from the AGAMENON-SEOM registry","volume":"149","author":"Valcarcel S","year":"2023","unstructured":"Valcarcel S, Gallego J, Jimenez-Fonseca P,  Does HER2 status influence in the benefit of ramucirumab and paclitaxel as second line treatment of advanced gastro-esophageal adenocarcinoma? Data from the AGAMENON-SEOM registry. J Cancer Res Clin Oncol 2023;149:4077\u20134089."},{"key":"B26","series-title":"Sci Rep","first-page":"3135","article-title":"Discordance in HER2 status in gastro-esophageal adenocarcinomas: a systematic review and meta-analysis","volume":"7","author":"Creemers A","year":"2017","unstructured":"Creemers A, Ter Veer E, de Waal L,  Discordance in HER2 status in gastro-esophageal adenocarcinomas: a systematic review and meta-analysis. Sci Rep 2017;7:3135."},{"key":"B27","series-title":"Oncotarget","first-page":"26787","article-title":"The dynamics of HER2 status in esophageal adenocarcinoma","volume":"9","author":"Creemers A","year":"2018","unstructured":"Creemers A, Ebbing EA, Hooijer GKJ,  The dynamics of HER2 status in esophageal adenocarcinoma. Oncotarget 2018;9:26787\u201326799."},{"key":"B28","series-title":"J Clin Med","article-title":"Novel biomarkers of gastric cancer: current research and future perspectives","volume":"12","author":"Sato Y","year":"2023","unstructured":"Sato Y, Okamoto K, Kawano Y,  Novel biomarkers of gastric cancer: current research and future perspectives. J Clin Med 2023;12:4646."},{"key":"B29","series-title":"Cell Oncol","first-page":"57","article-title":"HER2 expression in gastric cancer: rare, heterogeneous and of no prognostic value-conclusions from 924 cases of two independent series","volume":"32","author":"Grabsch H","year":"2010","unstructured":"Grabsch H, Sivakumar S, Gray S,  HER2 expression in gastric cancer: rare, heterogeneous and of no prognostic value-conclusions from 924 cases of two independent series. Cell Oncol 2010;32:57\u201365."},{"key":"B30","series-title":"Ther Adv Med Oncol","first-page":"17588359231162576","article-title":"Comparing treatment and outcomes in advanced esophageal, gastroesophageal junction, and gastric adenocarcinomas: a population-based study","volume":"15","author":"Pape M","year":"2023","unstructured":"Pape M, Vissers PAJ, Dijksterhuis WPM,  Comparing treatment and outcomes in advanced esophageal, gastroesophageal junction, and gastric adenocarcinomas: a population-based study. Ther Adv Med Oncol 2023;15:17588359231162576."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/23\/10\/article-e257058.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/23\/10\/article-e257058.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/23\/10\/article-e257058.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T12:35:48Z","timestamp":1760013348000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/23\/10\/article-e257058.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":30,"journal-issue":{"issue":"10"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2025.7058","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]}}}